Get started
$RHM now beneath 1500 E and the Weekly 50 MA - Can it bounce?XETR:RHM has had a fabulous run since the start of the Ukraine War. It has contributed to the DAX making new highs up until the summer of 25. However as mentioned elsewhere the possibility of a Ukraine Peace Plan has taken the lustre of European aerospace and defence stock, and RHM has been hit hard. From tickling the soft underbelly of 2000 Euros were no beneath 1500 Euros and also beneath the weekly 50 Moving Average. Is this where it bounces, or do we see more moves lower? Personally, I think any kind of peace agreement means we move lower, and i wonder if we head back to the 1000 Euro area. However if the peace plan is scuppered then we're likely to reclaim the 50MA and the 1500 Euro level...though it may not return to the highs of 2000 Euro. This will be a case of watching the news, and taking the lead from the negotiations. I wish for a just peace...but i winder if there's too many people making too much money out of the Ukraine War to allow it to end any time soon. Or is that just me being a cynical old b*stard?
XETR:RHMShort
by FXTraderPaul
Sub Wave 3 of Wave 3 imminent?Since end of November we just completed an inverse SKS formation on the daily charts, which is a bullish pattern. Also noticeable is a much higher trade volume since late last summer. Time to look into possible target zones: Sub (3) should go up to the 1,618 fib at least, maybe after a quick retest of the resistances marked in red Since the (3) and 3 waves share almost the same target i expect the Wave 3 to reach a higher fib lvl. In the past the 3,618 oder even 4,618 fib lvls were possible.
TRADEGATE:11LLong
by robschulz
Novo Nordisk: The European Giant Challenging Alphabet Novo Nordisk: The European Giant Challenging Alphabet in the Debt Market By Ion Jauregui – Analyst at ActivTrades The European corporate debt market closes 2025 with a surprise: Alphabet becomes the largest issuer of euro-denominated bonds of the year, with €13.25 billion placed and 3.1% of the total issued volume. However, the Danish company Novo Nordisk, Europe’s capitalization leader, positions itself as its main competitor, with €12.7 billion in issuances. Interest in both companies reflects the search for defensive and growth assets, but in the case of Novo Nordisk, the fundamentals provide unmatched strength. Fundamentals: Solid Growth and Structural Demand Novo Nordisk continues to expand, driven by its flagship drugs for diabetes and obesity (Ozempic and Wegovy), consolidating a business model with exceptional margins. • Annual growth: over 20% • Operating margin: above 44% • Solid cash position: even after investments in production capacity • Future market: obesity could exceed 1 billion global patients by 2030 The biopharmaceutical company does not issue debt out of necessity, but to finance industrial expansions and capture a rapidly growing healthcare market. The Debate: Bubble in the Debt Market? The rise in European issuances, especially from technology and pharmaceutical companies, has led some fund managers to warn of a possible bubble due to concentration rather than valuation. Unlike other issuers, Novo Nordisk maintains solid fundamentals that justify demand for its bonds, placing it among the safest issuers in Europe. Technical Analysis: Consolidation with Bullish Bias Since its all-time highs in June 2024, when it reached €134.14, the company’s stock corrected to a low in August 2025 around €38.09. This Monday, the price showed a technical rebound, closing yesterday at €42 after a week of bullish performance. If the price manages to retake the previous consolidation range, between €53.46 and €61.11, we could anticipate a more significant advance. For now, the stock is near the €42.5 consolidation zone, coinciding with the point of control (POC), a key accumulation and support level. Technical indicators show mixed signals: the RSI is recovering at 45.06%, while the MACD confirms a positive evolution with the histogram in positive territory. However, the moving average crossover does not yet fully support the bullish trend: the price remains around the 50-day moving average, while the 100- and 200-day moving averages are still sloping downward. In terms of scenarios, if the price fails to hold the annual low, we could see a bearish continuation toward €30. Conversely, if the support, which has been tested three times, holds, a clear upward rebound is possible. According to ActivTrades Europe Market Pulse, market sentiment shows a risk-on bias, although the overall situation remains neutral for now, reflecting caution among investors. European Benchmark Novo Nordisk confirms its position as one of the most solid European benchmarks, both in the debt and equity markets. Its structural growth, sustained demand for its treatments, and financial discipline distinguish it from competitors such as Alphabet and Volkswagen. Although technical analysis shows critical support levels that will condition the next price movement, the stock maintains a bullish recovery bias, supported by positive indicators and a market still favorable to controlled risk. Overall, Novo Nordisk combines stability and growth potential, consolidating itself as a defensive and strategic investment for investors seeking exposure to a leading European biopharmaceutical company. ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance and forecasting are not a synonym of a reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk. Political risk is unpredictable. Central bank actions can vary. Platform tools do not guarantee success.
XETR:NOV
by ActivTrades
SAP - could this be the top for the main driver of the DAX ?SAP has the highest market cap in the DAX (315 billion €) and has had an impressive run since the 2022 lows. Price shot up from 80 to 280 in one steep channel. Looking at the chart since the IPO, you can see a five wave structure that might have come to an end at the upper trendline of the channel. The DAX has dropped by 700 points this week and if SAP starts correcting to a conservative 0.764 retracement of this move, we are looking at a drop to 236. The MACD and RSI could certainly use a cooldown.
XETR:SAP
by flightleader78
1
New to trading: My analysis on DTE (Support Test & Breakout?)Hi everyone, I am new to trading and practicing my technical analysis. I would appreciate your feedback on this setup for Deutsche Telekom (DTE). My Analysis: Support: It looks like DTE recently tested a key support level where the descending trend line intersects with the Fibonacci levels. Target 1: Since this support held, I expect the price to move up towards 28.35 in the short term. This looks like a key test of the previous horizontal resistance (which also lines up with a Fibonacci level). Target 2: If the price successfully breaks through that resistance, I am looking at 29.2 as the next resistance level based on the current downtrend structure.
TRADEGATE:DTELong
by haozi4272
2
Airbus SE Accelerates Production as Tension Grows with Suppliers By Ion Jauregui – Analyst at ActivTrades Airbus SE is once again at the center of industrial attention. The European manufacturer is standing firm on its ambitious plan to ramp up A320neo production to 75 aircraft per month by 2027, but pressure on the supply chain — particularly engine suppliers — threatens to disrupt the timeline. According to industry sources, Pratt & Whitney, a subsidiary of RTX Corp (NYSE:RTX), is engaged in intensive negotiations with Airbus to secure engine deliveries beyond 2027. Although the supplier has already fulfilled the commitments agreed for 2025, tensions continue to rise. The reason: accumulated delays in repairs of its GTF engines, which have left hundreds of aircraft grounded worldwide over the past months. The situation is delicate enough that Airbus is forced to manage fuselage production while also handling a growing inventory of “gliders” — aircraft that are technically completed but lack engines. In this context, the battle between Pratt & Whitney and CFM International — the alliance between GE Aerospace and Safran SA (EPA:SAF) — is intensifying. Both groups compete to power the backbone of the global narrow-body fleet, yet neither is immune to capacity constraints and maintenance-shop bottlenecks. Industrial and Financial Impact The challenge for Airbus is significant. Airlines are pushing to receive their orders at a time when demand for single-aisle aircraft is at historic highs. For the company, meeting production targets is essential to sustain revenues, margins, and cash flow in the coming years. Engine delays have forced Pratt & Whitney to prioritize critical repairs, slowing the delivery of new units. Although Airbus has not officially revised its guidance, several European and Middle Eastern airlines warn that bottlenecks could extend into 2027, coinciding with the most demanding phase of the production ramp-up. Technical Analysis: Airbus SE (AIR.GE) Since April, Airbus SE (EPA:AIR) has maintained an upward trend and, in recent sessions, has been trading near the upper end of its current range, between €216.85 and €198.15, reflecting market confidence in the structural growth of the aerospace sector. However, the stock is showing resistance near the indicated all-time highs, where the price appears to be consolidating as investors await updates on the supply chain. Any signs of stabilization in the engine-related issues could act as a bullish catalyst. Conversely, new inspections, extended delays, or any news suggesting further disruptions could trigger technical corrections toward key support levels. From a technical standpoint, the current price fluctuates around the 50-day moving average, after having lost it in the previous session. The RSI sits at a neutral 49.82%, while the MACD appears to have entered corrective territory. ActivTrades Europe Market Pulse indicates that speculation and risk sentiment in the European market are neutral, suggesting that the current price action reflects a consolidation phase following the recent highs. Market Outlook For Airbus, the equation is clear: demand is strong, the backlog is solid, and financing is not an issue. However, the supply chain — particularly engine providers — remains the Achilles’ heel of global aviation. For the European manufacturer, Pratt & Whitney’s ability to meet deadlines will determine whether 2027 becomes a year of full expansion or one marked by delays in one of the most ambitious industrial plans of the decade. ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance and forecasting are not a synonym of a reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk. Political risk is unpredictable. Central bank actions can vary. Platform tools do not guarantee success.
XETR:AIRLong
by ActivTrades
ROYAL PALACE COURTS MAIN BOARD The National Government of Malaysia, in accordance with the 1957 Constitution of Independent State, amended the law to allow any person holding a title within the Royal Palace to have their title revoked directly by the AI system/or Lee Chee Keong if they are found guilty of misuse of public funds, money laundering, fraud, or involvement in war. The Supreme Royal Court can sentence such individuals to death or imprisonment for 20 years, and even a 100-year-old can be sentenced to death in a prison hospital until their passing. NYSE:AG OTC:ROYL
TRADEGATE:3BY3Long
by Keonglee7
THE COST OF HAIIUCINSTION In 2023 Stephen A Schwartz personal injury attorney with over 30year experience wae fines- along with his firm ,$5000.00 for using chatGPT as part of research into case he was handling for using chatGPT as part of research into a case he was handling for a client against the airline avianca, Schwartz after hearing (it) was the a super search engine and used it to try and uncover legal precedent for the case .the results according to direct judge peter kelvin castell contained gibberish and nonsensical claims including fake quote,this highlight the changer of falling to properly verify the outputs of LLMs
TRADEGATE:3BY3Long
by Keonglee7